Core Viewpoint - The commercialization of Jinbo Biotechnology (832982.BJ) remains a significant issue as the company faces industry-wide challenges, with growth rates slowing down despite maintaining revenue and profit increases [2][3]. Financial Performance - In the first three quarters of 2024, the company achieved revenue of 1.296 billion yuan, a year-on-year increase of 31.10%, and a net profit attributable to shareholders of 568 million yuan, up 9.29% [2]. - The company's revenue growth has significantly slowed compared to previous years, with the first half of 2024 showing the lowest growth rates in nearly five years [3]. - In Q3 2024, revenue grew by 13.36%, but the net profit excluding non-recurring items decreased by 16.72%, and net cash flow fell by 8.05% year-on-year [3]. Product Performance - The performance of the company's flagship product, Wei Yimei, which is the only approved Class III recombinant collagen injection in China, is declining, contributing 645 million yuan in revenue in the first half of 2024, a growth rate drop of over 70 percentage points [4]. - Conversely, the functional skincare product segment is emerging, generating 121 million yuan in revenue in the first half of 2024, a year-on-year increase of 152.39%, although its contribution to overall performance remains limited due to its smaller scale [4]. Market Dynamics - The company's stock price has experienced significant volatility, peaking at 577.50 yuan per share with a market cap exceeding 50 billion yuan, but later falling to 251.28 yuan per share and a market cap of 28.91 billion yuan, reflecting market re-evaluation of its growth logic [6][5]. - The industry is witnessing a collective slowdown, with competitors like Huaxi Biotechnology and Juzi Biotechnology also facing challenges, indicating a broader adjustment phase in the collagen market [2]. Strategic Adjustments - Jinbo Biotechnology possesses significant advantages in raw materials and technology, particularly with its recombinant human collagen technology, which has been validated through regulatory approvals [7]. - The company has historically focused on B2B pharmaceutical and medical device development, neglecting brand building and channel expansion in the consumer market [8]. - Recently, the company has begun to shift its strategy towards the consumer market, with initiatives such as collaborating with key opinion leaders and launching brand promotional campaigns [9]. - The ability to balance capital expectations with industry realities while establishing a consumer brand matrix will be crucial for the company's future growth [9].

Core Viewpoint - The medical beauty sector experienced a slight increase of 0.81% on October 31, with Jinbo Biological leading the gains, while the overall market indices saw declines [1]. Group 1: Market Performance - On October 31, the Shanghai Composite Index closed at 3954.79, down 0.81%, and the Shenzhen Component Index closed at 13378.21, down 1.14% [1]. - Jinbo Biological's stock price rose by 2.35% to 251.28, with a trading volume of 16,800 hands and a transaction value of 421 million yuan [1]. - Other notable stocks in the medical beauty sector included *ST Meigu, which increased by 1.42% to 3.58, and Huaxi Biological, which rose by 0.82% to 66.65 [1]. Group 2: Capital Flow - The medical beauty sector saw a net inflow of 5.8151 million yuan from institutional investors, while retail investors experienced a net outflow of 7.1663 million yuan [2]. - The sector also recorded a net inflow of 1.3512 million yuan from speculative funds [2].

Core Viewpoint - Jinbo Bio's revenue and net profit growth have slowed down following the challenge to its exclusive status in the "medical device three certificates" market, with the company reporting a significant decline in net profit for the third quarter of 2025 [2][3]. Financial Performance - For the first three quarters of 2025, Jinbo Bio reported revenue of 1.296 billion yuan, a year-on-year increase of 31.1%, and a net profit of 568 million yuan, up 9.29% year-on-year [2]. - In the third quarter of 2025, revenue was 437 million yuan, reflecting a year-on-year growth of 13.36%, while net profit decreased by 16.24% to 176 million yuan, marking the first quarterly net profit decline since the company's listing [2]. - The company's stock price fell by 7.07% to 245.5 yuan per share as of October 30, 2025, nearly a 50% drop since May of the same year [2]. Product and Market Dynamics - Wei Yimei, a key product of Jinbo Bio, has consistently contributed over 80% to the company's revenue, with its core component being recombinant humanized collagen, which is a Class III medical device approved by the National Medical Products Administration [3]. - Jinbo Bio held three "medical device three certificates" for recombinant collagen products, which have been crucial for its high growth, with revenue increasing from 102 million yuan in the first half of 2021 to 859 million yuan in the first half of 2025, representing a compound annual growth rate of 69.9% [3]. - The exclusive market position of Jinbo Bio has been challenged by the recent approval of a "medical device three certificate" for a competing product from Juzi Bio, marking the entry of additional players into the recombinant collagen market [3][4]. Competitive Landscape - Other leading medical aesthetic companies are also applying for "medical device three certificates" in the recombinant collagen sector, including Chuangjian Medical and Huaxi Bio, indicating increasing competition [4]. - Jinbo Bio's management stated that the company still possesses three certificates as technical support and maintains advantages in technology accumulation and product matrix in the recombinant collagen implant market [4]. Business Segmentation - Jinbo Bio's revenue growth is attributed to both medical devices and functional skincare products, with the latter seeing a significant increase of 152% in revenue growth in the first half of 2025 [5]. - The contribution of medical devices to Jinbo Bio's revenue decreased from 88% in the first half of 2024 to 82.5% in the first half of 2025, while the share of functional skincare products rose from 8% to 14% [5].

Core Insights - The medical beauty sector experienced a decline of 0.81% on October 30, with Jinbo Biological leading the drop at 7.07% [1] - The Shanghai Composite Index closed at 3986.9, down 0.73%, while the Shenzhen Component Index closed at 13532.13, down 1.16% [1] Medical Beauty Sector Performance - Huaxi Biological closed at 53.55, down 0.70%, with a trading volume of 30,900 shares and a transaction value of 166 million [1] - *ST Meigu closed at 3.53, down 0.84%, with a trading volume of 71,000 shares and a transaction value of 25.09 million [1] - Aimeike closed at 158.89, down 0.89%, with a trading volume of 30,100 shares and a transaction value of 47.9 million [1] - Jinbo Biological closed at 245.50, down 7.07%, with a trading volume of 29,300 shares and a transaction value of 733 million [1] Capital Flow Analysis - The medical beauty sector saw a net outflow of 2.1553 million from main funds, while retail funds experienced a net outflow of 3.2717 million [1] - Speculative funds had a net inflow of 5.4269 million [1] Individual Stock Capital Flow - Aimeike had a net outflow of 15.355 million, down 3.21%, with a net inflow of 21.139 million, down 0.44% [2] - *ST Meigu experienced a net outflow of 5.6326 million, down 22.45%, with a net inflow of 4.3275 million, up 17.25% [2] - Huaxi Biological had a net outflow of 13.9915 million, down 8.41%, with a net inflow of 16.4544 million, up 9.89% [2]

Core Insights - The company reported a total revenue of 1.296 billion yuan for the first three quarters of 2025, representing a year-on-year growth of 31.10%, and a net profit attributable to shareholders of 568 million yuan, up 9.29% year-on-year, driven by continuous investment in research and innovation [2] Group 1: Financial Performance - The company achieved a total revenue of 1.296 billion yuan in the first three quarters of 2025, marking a 31.10% increase compared to the previous year [2] - The net profit attributable to shareholders reached 568 million yuan, reflecting a year-on-year growth of 9.29% [2] Group 2: Product Development and Innovation - The company received registration for "recombinant type III humanized collagen protein lyophilized fibers" as a pharmaceutical excipient, marking a significant milestone in its development history and indicating the entry of recombinant collagen materials into core pharmaceutical applications [3] - The new material has broad application prospects in various fields, including injectables, biological agents, and topical preparations, particularly as a drug carrier for targeted delivery and sustained release [3] - The successful registration of the pharmaceutical excipient demonstrates the company's core technological advantages and continuous innovation capabilities in the field of recombinant humanized collagen [3] Group 3: Research and Development - The company's R&D expenses reached 71.2616 million yuan, a year-on-year increase of 64.31%, driven by increased collaboration with universities and research institutions, as well as a rise in research projects [4] - The company has established a dual-driven model of "independent innovation + joint research," effectively integrating resources for basic research and industrialization [4] - The company led an international standard proposal on medical devices, marking a significant breakthrough in the international standardization of bioengineering medical devices in China [4] Group 4: Digital Transformation and AI Integration - The company developed the "AI Collagen Brain System," which includes six core technology platforms for high-throughput screening, structural research, and efficient biosynthesis [5] - The "AI Collagen Brain System" was recognized as a national-level case in the Ministry of Industry and Information Technology's 2025 digital transformation case collection, indicating its leading position in digital transformation [6] - The integration of AI in production processes has significantly improved efficiency, with reports indicating a tenfold increase in fermentation process optimization [6]

Core Insights - Jinbo Bio reported a revenue of 1.296 billion yuan for the first three quarters of 2025, representing a year-on-year increase of 31.1% [1] - The net profit attributable to shareholders for the same period was 568 million yuan, showing a year-on-year growth of 9.29% [1] - In the third quarter alone, the company achieved a revenue of 437 million yuan, which is a year-on-year increase of 13.36% [1] - However, the net profit for the third quarter decreased by 16.24% to 176 million yuan compared to the same period last year [1] - Following the earnings report, Jinbo Bio's stock price fell sharply, dropping over 7% at one point on October 30 [1]

Core Viewpoint - Jinbo Biological (920982) experienced a block trade on October 28, with a transaction volume of 10,800 shares and a transaction amount of 2.2324 million yuan, at a price of 206.00 yuan, which represents a discount of 16.21% compared to the closing price of the day [2] Group 1: Block Trade Details - The block trade involved a total volume of 10,800 shares and a total transaction amount of 2.2324 million yuan [2] - The transaction price was 206.00 yuan, reflecting a discount of 16.21% relative to the closing price of the day [2] - The buyer was from Guojin Securities Co., Ltd. Shanghai Jing'an District Nanjing West Road Securities Business Department, while the seller was from Guojin Securities Co., Ltd. Shenzhen Branch [2] Group 2: Recent Trading Activity - In the past month, Jinbo Biological has recorded a total of 3 block trades, with a cumulative transaction amount of 7.2333 million yuan [2] - The closing price of Jinbo Biological on the day of the block trade was 245.86 yuan, which represents a decline of 2.05%, with a turnover rate of 2.21% and a total transaction amount of 299 million yuan [2] - Over the last 5 days, the stock has seen a cumulative decline of 6.83% [2] Group 3: Company Background - Shanxi Jinbo Biological Pharmaceutical Co., Ltd. was established on March 28, 2008, with a registered capital of 1,150.6534 million yuan [2]

Core Viewpoint - The medical beauty sector experienced a decline of 1.44% on October 28, with Jinbo Biological leading the drop. The Shanghai Composite Index closed at 3988.22, down 0.22%, while the Shenzhen Component Index closed at 13430.1, down 0.44% [1]. Group 1: Market Performance - The medical beauty sector's individual stock performance showed the following results: - Huaxi Biological closed at 52.72, down 1.03% with a trading volume of 18,000 shares and a transaction value of 95.6261 million yuan [1]. - *ST Meigu closed at 3.56, down 1.39% with a trading volume of 130,900 shares and a transaction value of 47.2460 million yuan [1]. - Aimeike closed at 163.54, down 1.74% with a trading volume of 32,100 shares and a transaction value of 529 million yuan [1]. - Jinbo Biological closed at 245.86, down 2.05% with a trading volume of 12,100 shares and a transaction value of 299 million yuan [1]. Group 2: Capital Flow - On the same day, the medical beauty sector saw a net outflow of 35.3969 million yuan from main funds, a net outflow of 24.4121 million yuan from speculative funds, and a net inflow of 59.809 million yuan from retail investors [2].

Core Insights - A block trade of 15,900 shares of Jinbo Biological (920982) occurred on October 27, with a transaction value of 3.9909 million yuan at a price of 251.00 yuan per share [1] - The buyer was Huatai Securities Co., Ltd. Kunshan Heilongjiang North Road Securities Business Department, and the seller was Guojin Securities Co., Ltd. Shenzhen Branch [1] Trading Activity - In the past month, Jinbo Biological has recorded a total of 2 block trades, amounting to a cumulative transaction value of 5.0009 million yuan [1] - The closing price of Jinbo Biological on the day of the block trade was 251.00 yuan, reflecting a decrease of 2.15%, with a daily turnover rate of 2.12% and a total trading volume of 293 million yuan [1] - Over the last five days, the stock has seen a cumulative decline of 3.83% [1] Company Background - Shanxi Jinbo Biological Pharmaceutical Co., Ltd. was established on March 28, 2008, with a registered capital of 1,150.6534 million yuan [1]

Core Insights - A competitive battle is emerging in the collagen protein market, highlighting two regional female tycoons, Fan Daidi from Shaanxi and Yang Xia from Shanxi, who are leading their respective companies, Juzhi Biotechnology and Jinbo Biotechnology, into the spotlight [1] Group 1: Market Dynamics - Both companies are shifting focus towards the C-end beauty market, particularly in the live e-commerce space, as evidenced by the rapid rise of the new brand "Tongping" during major shopping events [2][4] - The brand "Tongping" achieved significant sales during the Double 11 event, with a GMV growth rate ranking second in Li Jiaqi's live broadcast, while Juzhi's own brand, Kefu Mei, ranked seventh [2][6] Group 2: Company Performance - Juzhi Biotechnology's stock price has been on a downward trend, hitting a year-low of 40.40 HKD per share, with a total market capitalization dropping to 43.3 billion HKD [2][3] - Jinbo Biotechnology's stock has also faced declines, closing at 256.51 CNY per share with a total market value of 30.032 billion CNY as of October 24 [2] Group 3: Product and Brand Strategy - "Tongping" was launched in September 2024, focusing on technology-driven skincare solutions, with a limited number of core products [5][6] - The brand's rapid growth is attributed to strategic partnerships with top influencers, leading to significant sales during promotional events [6][8] Group 4: Technological and Competitive Landscape - The competition is intensifying as Jinbo Biotechnology transitions from B-end medical devices to C-end functional skincare, indicating a broader shift in the industry [3][11] - Jinbo Biotechnology has provided technological support to "Tongping," utilizing its patented collagen components in the brand's products, showcasing a close relationship between the two entities [9][10] Group 5: Investment and Future Outlook - Jinbo Biotechnology has recently secured investment from Zhong Shanshan, founder of Nongfu Spring, indicating strong backing for its strategic initiatives [11] - The ongoing competition reflects a blurring of lines between pharmaceutical and beauty companies, as the functional skincare market evolves from a blue ocean to a red ocean, with both companies vying for market leadership [11]